In Brief: Creative Biomolecules/Stryker
This article was originally published in The Gray Sheet
Executive Summary
Creative Biomolecules/Stryker: Extend development and commercialization agreement for OP-1 for orthopedic reconstruction with an investment of $12 mil. in new funding from Stryker. Filing of a premarket approval application is anticipated in "late 1997," CBM says. Target patient accrual in the pivotal trial of OP-1 for non-union fractures was completed in January 1996 and treated patients are in the required follow-up period, CBM says. Stryker also is conducting a supplemental study of OP-1 for "all long bone non-union fractures." Additional clinical studies in "a broadening array of orthopedic indications" are expected to be initiated in the U.S. and other countries "over the next 12 months"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.